May 2011: Capital increase with entry of new partners. Azurebio has finalised a capital increase of €800.000 with entry of venture capitals Fitalent (Everis Group) and Real de Vellon (Clave Mayor) and industrial partners Geiser Pharma and Galenicum Health, and a €350.000 loan from ENISA. Read more.

June 2010: AzureBio moves to new offices and laboratories in Tres Cantos (Madrid). This move provides full independence and larger laboratory and office space.

May 2010: AzureBio establishes formal collaboration with Instituto de Ceramica y Vidrio from the Consejo Superior de Investigaciones Cientificas. The collaboration provides access to first class material scientists and latest equipment for material characterisation.

March 2010: AzureBio establishes formal collaboration with Instituto de Polímeros from the Consejo Superior de Investigaciones Cientificas. The collaboratin provides access to first class polymer scientists.

April 2010: AzureBio presents investment opportunity at "V Foro de Inversion Madrid+D".

Dec 2009: Completed evaluation of Injectable Needles loaded with Hepatitis B vaccine. Studies carried out at Vivotecnia Research demonstrated efficacy and feasibility of AzureBio injectable needles loaded with Hepatitis B surface antigen and their equivalence to standard commercial vaccine.

April 2009: AzureBio establishes a formal collaboration with Centro de Cirugia Minima Invasiva Jesus Uson. The collaboration provides access to first class surgery and will facilitate the evaluation of new bone regeneration matrices.